ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

VIGL Vigil Neuroscience Inc

3.03
0.29 (10.58%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Vigil Neuroscience Inc VIGL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.29 10.58% 3.03 15:46:47
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.72 2.67 3.05 3.03 2.74
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/4/202415:05GLOBEVigil Presents Key Findings from ILLUMINATE & IGNITE Studies..
26/3/202406:05GLOBEVigil Neuroscience Reports Fourth Quarter and Full Year 2023..
20/3/202406:05GLOBEVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief..
13/3/202406:05GLOBEVigil Announces Upcoming Presentations at 2024 American..
12/3/202406:05GLOBEVigil Neuroscience to Present at Stifel 2024 Virtual CNS..
06/3/202415:25GLOBEVigil Announces Oral Presentation on Small Molecule TREM2..
01/3/202417:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202416:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:05GLOBEVigil Presents Poster on Impacts of Misdiagnosis and Genetic..
14/2/202410:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202415:05GLOBEVigil Neuroscience to Present at Guggenheim 6th Annual..
11/1/202409:30EDGAR2Form 8-K - Current report
03/1/202415:30GLOBEVigil Neuroscience Provides 2023 Year-in-Review and..
22/11/202315:05GLOBEVigil Neuroscience to Present at Evercore ISI 6th Annual..
16/11/202315:31EDGAR2Form 8-K - Current report
16/11/202315:05GLOBEVigil Neuroscience Reports Positive Interim Data from Phase..
07/11/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:15EDGAR2Form 8-K - Current report
07/11/202306:05GLOBEVigil Neuroscience Reports Third Quarter 2023 Financial..
17/10/202306:05GLOBEVigil Neuroscience Announces First Participant Dosed in..
12/10/202315:06EDGAR2Form 8-K - Current report
05/10/202315:01GLOBEVigil Neuroscience to Present at Jefferies Inaugural Biotech..
26/9/202306:05GLOBEVigil Neuroscience Receives Positive Opinion from European..
13/9/202306:31EDGAR2Form 8-K - Current report
11/9/202311:00GLOBEVigil Neuroscience Presents VGL101 Complete Phase 1 Data and..
08/9/202315:10EDGAR2Form 8-K - Current report
08/9/202315:05GLOBEVigil Neuroscience Announces Update on its Small Molecule..
08/9/202306:05GLOBEVigil Neuroscience to Present at 2023 Morgan Stanley Global..
08/8/202306:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:19EDGAR2Form 8-K - Current report
08/8/202306:05GLOBEVigil Neuroscience Reports Second Quarter 2023 Financial..
07/8/202317:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202317:38EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/8/202315:05GLOBEVigil Neuroscience Appoints Christopher J. Silber, M.D. as..
01/6/202306:00GLOBEVigil Neuroscience to Present at 2023 Jefferies Global..
10/5/202306:00GLOBEVigil Neuroscience Reports First Quarter 2023 Financial..
09/5/202306:00GLOBEVigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D...
08/5/202306:08GLOBEVigil Neuroscience Launches ALSPAware to Provide Access to..

Su Consulta Reciente

Delayed Upgrade Clock